ALX ONCOLOGY HOLDINGS

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

11 11 2021 16:05:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

09 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting

04 11 2021 09:00:02 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

02 11 2021 09:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

21 10 2021 07:00:02 提供 Nasdaq GlobeNewswire

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

07 10 2021 07:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 10 2021 08:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

16 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

07 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

12 8 2021 16:05:03 提供 Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

28 7 2021 07:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

03 7 2021 07:15:00 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

14 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

10 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

18 5 2021 07:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

17 5 2021 16:05:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

10 5 2021 07:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

21 4 2021 16:05:00 提供 Nasdaq GlobeNewswire

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

05 4 2021 07:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

18 3 2021 16:05:00 提供 Nasdaq GlobeNewswire